Influence of single hemodialysis session on serum paraoxonase-1, arylesterase activity, total oxidant status and total antioxidant status

Minerva Medica

Volumn 105, Issue 1, 2014, Pages 79-87

  Yildiz, G ^a   Aydin, H ^b   Magden K ^c   Yilmaz, A ^d   Hur E ^c   Candan, F ^b  

^a Ataturk State Hospital   (Turkey)

^b CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^d GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Hemodialysis; Oxidative stress

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HYDROGEN PEROXIDE; OXIDIZING AGENT; REACTIVE OXYGEN METABOLITE; TROLOX C;

ADULT; ANTIOXIDANT ACTIVITY; ANTIOXIDANT ASSAY; ARTICLE; CLINICAL ARTICLE; END STAGE RENAL DISEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; MALE; METABOLIC PARAMETERS; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; OXIDATIVE STRESS INDEX; TOTAL ANTIOXIDANT STATUS; TOTAL OXIDANT STATUS; TREATMENT DURATION;

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; CHROMANS; FEMALE; HUMANS; HYDROGEN PEROXIDE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; TIME FACTORS;

EID: 84898471603     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001;16:335-40.
2. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 1999;17:99-106.
3. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37:277-85.
4. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-9.
5. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-11.
6. Martinelli N, Girelli D, Olivieri O, Cavallari U, Biscuola M, Trabetti E et al. Interaction between metabolic syndrome and PONT polymorphisms as a determinant of the risk of coronary artery disease. Clin Exp Med. 2005;5:20-30.
7. Gullulu M, Kahvecioglu S, Dirican M, Akdag I, Ocak N, Demircan C et al. Paraoxonase activity in glomerulonephritic patients. Ren Fail 2007;29:433-9.
8. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76.
9. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998;32:853-906.
10. Zoccali C. Cardiovascular risk in uraemic patients is it fully explained by classical risk factors? Nephrol Dial Transplant 2000;15:454-7.
11. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER. Oxidative stress in haemodialysis. Q J Med 1994;87:679-83.
12. Matteucci E, Cupisti A, Caprioli R, Battipaglia E, Favilla S, Rindi P et al. Erythrocyte transmembrane electron transfer in haemodialysis patients. Nutr Metab Cardiovasc Dis 2007;17:288-93.
13. Flora SJ. Role of free radicals and antioxidants in health and disease. Cell Mol Biol 2007;53.1-2.
14. Tepel M, Van Der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;25;107:992-5.
15. Raj DS, Lim G, Levi M, Qualls C, Jain SK. Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy. Am J Kidney Dis 2004;43:154-60.
16. Samouilidou EC, Grapsa EJ, Kakavas I, Lagouranis A, Agrogiannis B. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol 2003;35:393-7.
17. Çeliker H, Elkiran B, Ihan N, Günal A, Dogukan A. The effects of hemodialysis and peritoneal dialysis on oxidative parameters. Turkish Nephrology, Dialysis and Transplantation Journal 2001;10:88-92.
18. Herbelin A, Nguyen AT, Zingraff J, Ureña P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990;37:116-25.
19. Lander H. An essentiol role for free radicals and derived species in signal transduction. FASEB J 1997;11:118-24.
20. Clermont G, Lecour S, Lahet J, Siohan P, Vergely C, Chevet D et al. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000;47:618-23.
21. Chao JC, Yuan MD, Chen PY, Chien SW. Vitamin C and E supplements improve the impaired antioxidant status and decrease plasma lipid peroxides in hemodialysis patients small star, filled. J Nutr Biochem 2002;13.653-63.
22. Mimić-Oka J, Simić T, Djukanović L, Reljić Z, Davicević Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 1999;51:233-41.
23. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69:541-50.
24. Mackness B, McElduff P, Mackness MI. The paraoxonase-2-310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus. J Intern Med 2005;258:363-8.
25. Baum L, Ng HK, Woo KS, Tomlinson B, Rainer TH, Chen X et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 2006;39:191-5.
26. Ferretti G, Bacchetti T, Moroni C, Vignini A, Curatola G. Copper-induced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochim Biophys Acta 2003;1635:48-54.
27. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int 2008;12:471-9.
28. Horoz M, Aslan M, Selek S, Koylü AO, Bölükbaş C, Böülkbaş FF et al. PON1 status in haemodialysis patients and the impact of hepatitis C infection. Clin Biochem 2007;40:609-14.
29. Suehiro T, Ikeda Y, Shiinoki T, Inoue M, Kumon Y, Itahara T et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002,9:133-8.
30. Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004;17:813-8.
31. Itahara T, Suehiro T, Ikeda Y, Inoue M, Nakamura T, Kumon Y et al. Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb 2000;7:152-8.
32. Güngor O, Kircelli F, Demirci MS, Tuncel P, Sişman AR, Tatar E et al. Serum paraoxonase 1 activity predicts arterial stiffness in renal transplant recipients. J Atheroscler Thromb 2011;18.901-5.
33. Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazȧwa H, Inoue M et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysispatients. Clin Nephrol 2007;67:358-65.
34. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-8.
35. Galli F, Rovidati S, Chiarantini L, Campus G, Canestrari F, Buoncristiani U. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int 1998;54:580-9.
36. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 2001;59:108-13.
37. Suzuki YJ, Forman HJ, Sevanian A. Oxidants as stimulator of signal transduction. Free Radic Biol Med 1997;22:269-85.
38. Köken T, Serteser M, Kahraman A, Gökçe C, Demir S. Changes in serum markers of oxidative stress with varying periods of haemodialysis. Nephrology (Carlton) 2004;9:77-82.
39. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-83.
40. Cristol JP, Bose JY, Badiou S, Leblanc M, Lorrho R, Descomps B et al. Erythropoietin and oxidative stress in hemodialysis. Benefical effects of vitamin E supplementation. Nephrol Dial Transplant 1997;12 2312-7.